Tom Gayner Regeneron Pharmaceuticals, Inc. Transaction History

Markel Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 03, 2023	SELL	$705.89 - $766.39 $35.2 Million - $38.2 Million	-49,800 Reduced 62.02%	30,500 $22 Million
Q1 2022 Apr 29, 2022	BUY	$595.12 - $698.43 $595,120 - $698,430	1,000 Added 1.26%	80,300 $56.1 Million
Q4 2021 Feb 04, 2022	BUY	$543.48 - $670.97 $2.72 Million - $3.35 Million	5,000 Added 6.73%	79,300 $50.1 Million
Q3 2021 Nov 05, 2021	BUY	$574.03 - $680.96 $4.31 Million - $5.11 Million	7,500 Added 11.23%	74,300 $45 Million
Q2 2021 Aug 06, 2021	BUY	$472.8 - $558.54 $10.1 Million - $11.9 Million	21,300 Added 46.81%	66,800 $37.3 Million
Q1 2021 Apr 30, 2021	BUY	$446.73 - $548.2 $20.3 Million - $24.9 Million	45,500 New	45,500 $21.5 Million

1,534

83.6M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $76.7B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Markel Corp, based on Form 13F filings with the SEC.

Stay updated on Markel Corp and Tom Gayner with notifications on news.